Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 84 articles: HTML format

Single Articles

May 2026
1. WISEMAN DH, Batta K
   From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia.
   J Clin Oncol. 2026 May 7:JCO2600635. doi: 10.1200/JCO-26-00635.
   PubMed    
   
   
   April 2026
2. WIERDA WG, Leow CC, Ruppert AS, Bian Y, et al
   Reply to: How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.
   J Clin Oncol. 2026 Apr 20:JCO2600304. doi: 10.1200/JCO-26-00304.
   PubMed    
   
   
   
3. LEVY V, Chevret S
   How to Interpret the Results in a Noninferiority Randomized Trial in Chronic Lymphocytic Leukemia.
   J Clin Oncol. 2026 Apr 20:JCO2503114. doi: 10.1200/JCO-25-03114.
   PubMed    
   
   
   
4. RETTINGER E, Heckl D, Hutter M, Salzmann-Manrique E, et al
   First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.
   J Clin Oncol. 2026 Apr 6:JCO2501966. doi: 10.1200/JCO-25-01966.
   PubMed     Abstract available
   
   
   
5. PEMMARAJU N, Marconi G, Montesinos P, Lane AA, et al
   Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
   J Clin Oncol. 2026;44:861-873.
   PubMed     Abstract available
   
   
   March 2026
6. LANINO L, Hunter AM, Gagelmann N, Robin M, et al
   Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.
   J Clin Oncol. 2026 Mar 27:JCO2502116. doi: 10.1200/JCO-25-02116.
   PubMed     Abstract available
   
   
   February 2026
7. VIEIRA MARTINS M, de Lorenzo P, Kotecha RS, Attarbaschi A, et al
   Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.
   J Clin Oncol. 2026;44:370-374.
   PubMed     Abstract available
   
   
   January 2026
8. BRAUNSTEIN MJ, Williams ME
   Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.
   J Clin Oncol. 2026 Jan 20:JCO2502879. doi: 10.1200/JCO-25-02879.
   PubMed    
   
   
   December 2025
9. WINGARD JR, Lee JH, Li D, Al-Mansour Z, et al
   Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.
   J Clin Oncol. 2025 Dec 17:JCO2500889. doi: 10.1200/JCO-25-00889.
   PubMed     Abstract available
   
   
   
10. GOTTSCHALK H, Moricke A, Conter V, Schrappe M, et al
    Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.
    J Clin Oncol. 2025;43:3739-3749.
    PubMed     Abstract available
    
    
    
11. JURCZAK W, Kwiatek M, Czyz J, Roberto de Mattos E, et al
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    J Clin Oncol. 2025 Dec 9:JCO2502380. doi: 10.1200/JCO-25-02380.
    PubMed     Abstract available
    
    
    
12. DAVIDS MS
    BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2025 Dec 9:JCO2502691. doi: 10.1200/JCO-25-02691.
    PubMed    
    
    
    
13. WOYACH JA, Qiu L, Grosicki S, Wrobel T, et al
    Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    J Clin Oncol. 2025 Dec 7:JCO2502477. doi: 10.1200/JCO-25-02477.
    PubMed     Abstract available
    
    
    November 2025
14. SHARMAN JP, Liu B, Wang DY, Leow CC, et al
    Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
    J Clin Oncol. 2025 Nov 21:JCO2502231. doi: 10.1200/JCO-25-02231.
    PubMed    
    
    
    
15. CLIFF ERS, Lew TE, Simon F, Hilal T, et al
    Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.
    J Clin Oncol. 2025 Nov 21:JCO2501695. doi: 10.1200/JCO-25-01695.
    PubMed    
    
    
    
16. WIEDUWILT MJ, Yin J, Kour O, Teske R, et al
    Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
    J Clin Oncol. 2025;43:3526-3535.
    PubMed     Abstract available
    
    
    
17. WANG ES, Montesinos P, Foran J, Erba H, et al
    Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
    J Clin Oncol. 2025;43:3381-3390.
    PubMed     Abstract available
    
    
    October 2025
18. MONTESINOS P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, et al
    Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study.
    J Clin Oncol. 2025 Oct 13:101200JCO2501841. doi: 10.1200/JCO-25-01841.
    PubMed     Abstract available
    
    
    August 2025
19. DINARDO CD, Marvin-Peek J, Loghavi S, Takahashi K, et al
    Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
    J Clin Oncol. 2025;43:2692-2699.
    PubMed     Abstract available
    
    
    
20. PLATZBECKER U, Ades L, Montesinos P, Ammatuna E, et al
    Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
    J Clin Oncol. 2025 Aug 18:JCO2500535. doi: 10.1200/JCO-25-00535.
    PubMed     Abstract available
    
    
    
21. ILAND HJ
    APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy.
    J Clin Oncol. 2025 Aug 18:JCO2501496. doi: 10.1200/JCO-25-01496.
    PubMed    
    
    
    
22. ZEIDNER JF, Lin TL, Welkie RL, Curran E, et al
    Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.
    J Clin Oncol. 2025;43:2606-2615.
    PubMed     Abstract available
    
    
    July 2025
23. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jul 29:JCO2501700. doi: 10.1200/JCO-25-01700.
    PubMed    
    
    
    June 2025
24. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jun 27:JCO2501356. doi: 10.1200/JCO-25-01356.
    PubMed    
    
    
    
25. HUANG BJ, Meyer LK, Alonzo TA, Wang YC, et al
    Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
    J Clin Oncol. 2025;43:1961-1971.
    PubMed     Abstract available
    
    
    
26. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jun 6:JCO2500166. doi: 10.1200/JCO-25-00166.
    PubMed     Abstract available
    
    
    May 2025
27. SHADMAN M, Munir T, Ma S, Lasica M, et al
    Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
    J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758.
    PubMed     Abstract available
    
    
    April 2025
28. KIRKWOOD AA, Goulden N, Moppett J, Samarasinghe S, et al
    High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.
    J Clin Oncol. 2025 Apr 7:JCO2401851. doi: 10.1200/JCO-24-01851.
    PubMed     Abstract available
    
    
    March 2025
29. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
    Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    J Clin Oncol. 2025 Mar 18:JCO2500466. doi: 10.1200/JCO-25-00466.
    PubMed    
    
    
    
30. TREGNAGO C, Benetton M, Ries RE, Peplinski JH, et al
    Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.
    J Clin Oncol. 2025;43:972-984.
    PubMed     Abstract available
    
    
    February 2025
31. RUSSELL NH, Thomas A, Hills RK, Thomas I, et al
    Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
    J Clin Oncol. 2025;43:694-704.
    PubMed     Abstract available
    
    
    
32. KATO M, Okamoto Y, Imamura T, Kada A, et al
    JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.
    J Clin Oncol. 2025;43:567-577.
    PubMed     Abstract available
    
    
    
33. ROLOFF GW, Aldoss I, Kopmar NE, Lin C, et al
    Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
    J Clin Oncol. 2025;43:558-566.
    PubMed     Abstract available
    
    
    January 2025
34. GYURKOCZA B, Nath R, Seropian S, Choe H, et al
    Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
    J Clin Oncol. 2025;43:201-213.
    PubMed     Abstract available
    
    
    December 2024
35. KANTARJIAN H, Short NJ, Haddad FG, Jain N, et al
    Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
    J Clin Oncol. 2024;42:4246-4251.
    PubMed     Abstract available
    
    
    
36. ROY A, Brander DM, Hill EG, Halabi S, et al
    Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Dec 12:JCO2401881. doi: 10.1200/JCO-24-01881.
    PubMed    
    
    
    
37. SHADMAN M, Munir T, Robak T, Brown JR, et al
    Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
    J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265.
    PubMed     Abstract available
    
    
    
38. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
    Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503.
    PubMed     Abstract available
    
    
    
39. VERSLUIS J, Metzner M, Wang A, Gradowska P, et al
    Risk Stratification in Older Intensively Treated Patients With AML.
    J Clin Oncol. 2024;42:4084-4094.
    PubMed     Abstract available
    
    
    November 2024
40. LANGERBEINS P, Robrecht S, Nieper P, Cramer P, et al
    Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
    J Clin Oncol. 2024 Nov 27:JCO2400975. doi: 10.1200/JCO.24.00975.
    PubMed     Abstract available
    
    
    
41. HEIKAMP EB, Armstrong SA
    Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia.
    J Clin Oncol. 2024 Nov 7:JCO2401265. doi: 10.1200/JCO-24-01265.
    PubMed    
    
    
    October 2024
42. CHEVALLIER P, Leguay T, Delord M, Salek C, et al
    Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22(+) Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Oct 17:JCO2400490. doi: 10.1200/JCO.24.00490.
    PubMed     Abstract available
    
    
    September 2024
43. ROLLIG C, Steffen B, Schliemann C, Mikesch JH, et al
    Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
    J Clin Oncol. 2024 Sep 16:JCO2400235. doi: 10.1200/JCO.24.00235.
    PubMed     Abstract available
    
    
    
44. KIM R, Chalandon Y, Rousselot P, Cayuela JM, et al
    Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.
    J Clin Oncol. 2024;42:3140-3150.
    PubMed     Abstract available
    
    
    
45. VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al
    Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.
    J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332.
    PubMed     Abstract available
    
    
    August 2024
46. SIMON F, Ligtvoet R, Robrecht S, Cramer P, et al
    Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Aug 30:JCO2401192. doi: 10.1200/JCO.24.01192.
    PubMed     Abstract available
    
    
    
47. CHANG TC, Chen W, Qu C, Cheng Z, et al
    Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Aug 9:JCO2302238. doi: 10.1200/JCO.23.02238.
    PubMed     Abstract available
    
    
    
48. ISSA GC, Aldoss I, Thirman MJ, DiPersio J, et al
    Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
    J Clin Oncol. 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826.
    PubMed     Abstract available
    
    
    
49. YOSHIMURA S, Li Z, Gocho Y, Yang W, et al
    Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Aug 5:JCO2400500. doi: 10.1200/JCO.24.00500.
    PubMed     Abstract available
    
    
    
50. TURCOTTE LM, Neglia JP
    Duress and Distress Versus a Neurocognitive Mess: The Challenges of Procedural Sedation in Pediatric B-ALL.
    J Clin Oncol. 2024;42:2628-2631.
    PubMed     Abstract available
    
    
    
51. ALEXANDER S, Kairalla JA, Gupta S, Hibbitts E, et al
    Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study.
    J Clin Oncol. 2024;42:2671-2679.
    PubMed     Abstract available
    
    
    July 2024
52. MATAVA CT, Peyton J, von Ungern-Sternberg BS, Ing C, et al
    Propofol, Anesthesia, and Neurocognitive Outcomes in Patients With Pediatric Leukemia: Are We Missing the Forest for the Trees?
    J Clin Oncol. 2024 Jul 24:JCO2400856. doi: 10.1200/JCO.24.00856.
    PubMed    
    
    
    June 2024
53. TIERENS A, Arad-Cohen N, Cheuk D, De Moerloose B, et al
    Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
    J Clin Oncol. 2024;42:2174-2185.
    PubMed     Abstract available
    
    
    
54. TIONG IS, Hiwase DK, Abro E, Bajel A, et al
    Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
    J Clin Oncol. 2024;42:2161-2173.
    PubMed     Abstract available
    
    
    
55. KITTAI AS, Bond D, Huang Y, Bhat SA, et al
    Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
    J Clin Oncol. 2024;42:2071-2079.
    PubMed     Abstract available
    
    
    
56. REED DR, Tulpule A, Metts J, Trucco M, et al
    Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials.
    J Clin Oncol. 2024 Jun 6:JCO2302717. doi: 10.1200/JCO.23.02717.
    PubMed     Abstract available
    
    
    May 2024
57. DAVER NG, Craddock C
    Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome.
    J Clin Oncol. 2024;42:1731-1733.
    PubMed    
    
    
    
58. WANG ES, Goldberg AD, Tallman M, Walter RB, et al
    Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1776-1787.
    PubMed     Abstract available
    
    
    
59. VAN DER SLUIS IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, et al
    Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
    J Clin Oncol. 2024;42:1676-1686.
    PubMed     Abstract available
    
    
    
60. SHORT NJ, Daver N, Dinardo CD, Kadia T, et al
    Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1499-1508.
    PubMed     Abstract available
    
    
    April 2024
61. TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
    Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    J Clin Oncol. 2024;42:1378-1390.
    PubMed     Abstract available
    
    
    
62. RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al
    Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
    J Clin Oncol. 2024;42:1158-1168.
    PubMed     Abstract available
    
    
    March 2024
63. BERMAN E, Shah NP, Deninger M, Altman JK, et al
    CML and the WHO: Why?
    J Clin Oncol. 2024;42:984-986.
    PubMed    
    
    
    
64. FEDELE PL, Opat S
    Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
    J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.
    PubMed    
    
    
    
65. LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al
    Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
    PubMed     Abstract available
    
    
    
66. MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al
    European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
    J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
    PubMed     Abstract available
    
    
    
67. FOA R, Bassan R, Elia L, Piciocchi A, et al
    Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
    J Clin Oncol. 2024;42:881-885.
    PubMed     Abstract available
    
    
    
68. CONTER V, Valsecchi MG, Cario G, Zimmermann M, et al
    Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
    J Clin Oncol. 2024;42:915-926.
    PubMed     Abstract available
    
    
    
69. HODDER A, Mishra AK, Enshaei A, Baird S, et al
    Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
    J Clin Oncol. 2024;42:907-914.
    PubMed     Abstract available
    
    
    January 2024
70. LOGAN A
    Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
    J Clin Oncol. 2024;42:250-252.
    PubMed    
    
    
    
71. STELLJES M, Raffel S, Alakel N, Wasch R, et al
    Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
    J Clin Oncol. 2024;42:273-282.
    PubMed     Abstract available
    
    
    
72. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    PubMed     Abstract available
    
    
    December 2023
73. PIETERS R, Mullighan CG, Hunger SP
    Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.
    J Clin Oncol. 2023;41:5579-5591.
    PubMed     Abstract available
    
    
    
74. LEE SHR, Ashcraft E, Yang W, Roberts KG, et al
    Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.
    J Clin Oncol. 2023;41:5422-5432.
    PubMed     Abstract available
    
    
    
75. RASHIDI A, Ebadi M, Rehman TU, Elhusseini H, et al
    Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
    J Clin Oncol. 2023;41:5306-5319.
    PubMed     Abstract available
    
    
    November 2023
76. BRIVIO E, Pennesi E, Willemse ME, Huitema ADR, et al
    Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
    J Clin Oncol. 2023 Nov 30:JCO2300897. doi: 10.1200/JCO.23.00897.
    PubMed     Abstract available
    
    
    
77. RAETZ EA, Rebora P, Conter V, Schrappe M, et al
    Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
    J Clin Oncol. 2023;41:5025-5034.
    PubMed     Abstract available
    
    
    
78. DAVER NG, Vyas P, Kambhampati S, Al Malki MM, et al
    Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
    J Clin Oncol. 2023;41:4893-4904.
    PubMed     Abstract available
    
    
    
79. LI J, Gao J, Liu A, Liu W, et al
    Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
    J Clin Oncol. 2023;41:4881-4892.
    PubMed     Abstract available
    
    
    October 2023
80. DEWOLF S, Tallman MS, Rowe JM, Salman MY, et al
    What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
    J Clin Oncol. 2023;41:4693-4703.
    PubMed     Abstract available
    
    
    
81. LING Y, Xuan L, Xu N, Huang F, et al
    Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    J Clin Oncol. 2023;41:4632-4642.
    PubMed     Abstract available
    
    
    September 2023
82. MCCAW ZR, Richardson PG, Wei LJ
    Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML.
    J Clin Oncol. 2023;41:4446-4447.
    PubMed    
    
    
    
83. 
    Erratum: Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
    J Clin Oncol. 2023 Sep 12:JCO2301844. doi: 10.1200/JCO.23.01844.
    PubMed    
    
    
    
84. PRATZ KW, Cherry M, Altman JK, Cooper BW, et al
    Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
    J Clin Oncol. 2023;41:4236-4246.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum